March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Inside MaTOS GU25: Insights from Chandler Park part 2
Mar 26, 2025, 01:41

Inside MaTOS GU25: Insights from Chandler Park part 2

The Masters in Therapeutic Oncology Summit – Genitourinary (GU) Edition (MaTOS GU25) brought together some of the brightest minds in GU oncology from March 20-23, 2025, at The Ballantyne, Charlotte.

This dynamic and highly specialized gathering fostered in-depth discussions on the latest advancements in the treatment of GU tumors.

With a focus on emerging therapies, evolving treatment strategies, and complex case analyses, MaTOS-GU created a collaborative space for oncologists to exchange insights and refine approaches that will ultimately improve patient care.

Inside MaTOS GU25: Insights from Chandler Park part 2

At OncoDaily, we are excited to share exclusive insights from Chandler Park, Advisory Dean and Clinical Professor at University of Louisville School of Medicine, who has been closely following the event. Through his updates, we bring you key takeaways from leading oncologists.
  1. Dr. Jonathan Rosenberg provides a tour de force Keynote presentation on Bladder Preservation with systematic therapy alone at MAToSGU25 . Loved the discussion of biomarker selected patients and future of systemic therapy for bladder preservation.

Inside MaTOS GU25: Insights from Chandler Park part 2

 

2. Dr. Guru Sonpavde provides an exceptional 2025 Update of Novel Biomarkers in Urothelial Cancer. Great discussion of potential biomarkers including deep learning, spatial transcriptomics, plasma proteomics.

Inside MaTOS GU25: Insights from Chandler Park part 2

3. Dr. Karine Tawagi presents a challenging prostate cancer case with robust panel discussion. Loved how she masterfully guided the conversations and discussed her rationale for immunotherapy treatment.

Inside MaTOS GU25: Insights from Chandler Park part 2

4. Dr. Amanda Nizam gives an outstanding Prostate cancer and liquid biopsies update including clinical application of ctDNA.

Inside MaTOS GU25: Insights from Chandler Park part 2

5. Leading expert Dr. Scott Tagawa provides an update on the PSMAddition and UpFrontPSMA studies evaluating the use of Lutetium 177 in the metastatic hormone sensitive setting.

Inside MaTOS GU25: Insights from Chandler Park part 2

6. Dr. Evan Yu gives a masterful discussion of emerging Novel Androgen Receptor Directed strategies in metastatic prostate cancer.

Inside MaTOS GU25: Insights from Chandler Park part 2

Inside MaTOS GU25: Insights from Chandler Park Part 1